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Abstract
Increased dietary intake of Selenium (Se) has been suggested to lower prostate cancer mortality, but supplementation trials
have produced conflicting results. Se is incorporated into 25 selenoproteins. The aim of this work was to assess whether risk
of prostate cancer is affected by genetic variants in genes coding for selenoproteins, either alone or in combination with Se
status. 248 cases and 492 controls from an EPIC-Heidelberg nested case-control study were subjected to two-stage
genotyping with an initial screening phase in which 384 tagging-SNPs covering 72 Se-related genes were determined in 94
cases and 94 controls using the Illumina Goldengate methodology. This analysis was followed by a second phase in which
genotyping for candidate SNPs identified in the first phase was carried out in the full study using Sequenom. Risk of high-
grade or advanced stage prostate cancer was modified by interactions between serum markers of Se status and genotypes
for rs9880056 in SELK, rs9605030 and rs9605031 in TXNRD2, and rs7310505 in TXNRD1. No significant effects of SNPs on
prostate cancer risk were observed when grade or Se status was not taken into account. In conclusion, the risk of high-grade
or advanced-stage prostate cancer is significantly altered by a combination of genotype for SNPs in selenoprotein genes
and Se status. The findings contribute to explaining the biological effects of selenium intake and genetic factors in prostate
cancer development and highlight potential roles of thioredoxin reductases and selenoprotein K in tumour progression.
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Introduction
The micronutrient Selenium (Se) is essential for human health
and sub-optimal intake has been suggested to increase risk of
various multifactorial diseases [1,2]. Increased dietary intake of Se
has been proposed to lower cancer mortality [3] and in particular
Se has been reported to have a protective effect against prostate
cancer [4], based partly on the results of a trial in the US that
found an additional 200 mg Se/day to lower prostate cancer
incidence in individuals who had relatively low Se status prior to
supplementation [5]. However, a second supplementation trial
(SELECT) failed to confirm this observation [6]. Although the
different outcomes of these trials are likely to be due to a higher
baseline Se status in the more recent SELECT study [7], they may
also be affected by differences in the characteristics of the
probands, such as pattern and prevalence of Se-related genetic
variants in the study cohorts.
The biological functions of Se are carried out primarily by
selenoproteins which contain Se in the form of the amino acid
selenocysteine [8] and it is likely that the anti-carcinogenic
properties of Se are brought about through these selenoproteins
[9]. The selenoproteins have functions in cellular antioxidant
protection (glutathione peroxidases, selenoproteins W and H), redox
control (thioredoxin reductases), Se transport (selenoprotein P), and
the endoplasmic reticulum unfolded protein response (selenoprotein
S, 15 kDa selenoprotein, selenoprotein K) [10]. GPx3 and
selenoprotein P (SePP) are secreted into the bloodstream and their
plasma level, as well as serum Se, are commonly used as markers of
Se status [11,12]. A functional interaction between selenoproteins
and prostate cancer has been reported, i.e. serum Se and
selenoprotein P (SePP) concentrations are reduced in prostate
cancer patients and this is correlated with disease severity [13]. This
in turn could reduce selenoprotein expression and associated anti-
oxidant defense resulting in increased oxidative damage leading to
prostate cancer progression [14].
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Selenocysteine incorporation into selenoproteins occurs during
translation and requires proteins such as SECIS-binding protein 2
(SBP2) [7,10]. Genetic variants in genes encoding the selenopro-
teins or components of the selenocysteine incorporation machinery
would be expected to influence the biological pathways that are
modulated by selenoproteins [15,16]. Indeed, functional single
nucleotide polymorphisms (SNPs) have been identified in a
number of selenoprotein genes [13,14] and disease association
studies have linked variants in SEPP1, GPX1, GPX4, SEP15 or
SELS to risk of various diseases [15,16]. Three recent studies have
studied the association of single selenoprotein gene variants with
prostate cancer risk [13,17,18] and importantly they suggest that
interactions between different SNPs in selenoprotein genes or
antioxidant protein genes and Se status may influence suscepti-
bility to prostate cancer or disease mortality. The common
mechanism by which Se is incorporated into selenoproteins, the
hierarchy of selenoprotein synthesis when Se supply is limited and
the related functions of several selenoproteins (e.g. in redox control
and unfolded protein response) all emphasise that selenoproteins
are components of an integrated metabolic pathway. This close
relationship between selenoproteins suggests that the influence of
genetics on selenoprotein function and related disease risk is
complex involving multiple interacting variants and both genetic
and nutritional factors. However, such a comprehensive study of
SNPs throughout the ‘‘Se pathway’’ in relation to prostate cancer
has not been carried out.
As the selenoprotein family and selenoprotein biosynthesis
pathway are well characterised, the aim of the present study was to
investigate the association between SNPs throughout the genes
encoding selenoproteins, factors essential for selenocysteine
incorporation and related antioxidant proteins, Se status (as
assessed by measurement of total serum Se, selenoprotein P (SePP)
concentration and serum glutathione peroxidase (GPx3) activity)
and prostate cancer risk in a European population with a Se status
lower than that found in the USA. To achieve this aim, DNA
samples from EPIC-Heidelberg, a prospective cohort study aiming
to evaluate the association between dietary, lifestyle and metabolic
factors and the risk of cancer, were genotyped and plasma samples
analysed for plasma selenium status, selenoprotein P concentration
and GPx activity. Previously, the samples had been analysed for
six selenoprotein SNPs and rs1053040 in GPX1 was found to
modulate the effect of serum Se on prostate cancer risk [13]. These
six SNPs were not examined in the present study but instead the
approach taken was a two-stage genotyping study: the first stage
was an unbiased hypothesis-generating phase in which genotyping
for 384 tagging-SNPs covering 72 Se-related genes (including
selenoprotein genes, selenoprotein synthesis machinery, factors
known to be influenced by selenoproteins, some related transcrip-
tion factors and genes in linkage disequilibrium with these genes)
was carried out in 94 advanced prostate cancer cases and an equal
number of matched controls; in the second phase genotyping for a
selected number of SNPs identified in the first phase was carried
out in all 492 cases and controls.
Methods
Study Population and Data Assessment
The EPIC-Heidelberg study was designed to evaluate the
association between dietary, lifestyle and metabolic factors and the
risk of cancer. A random sample of the general population of
Heidelberg, Germany, and surrounding communities was provid-
ed by the local registries and invited to participate. From 1994 to
1998, 11928 men (aged 40–64) and 13612 women (aged 35–64)
were recruited, comprising 38% of those approached [19]. Details
of the collection of dietary, lifestyle and socioeconomic data have
been described previously [13]. Blood samples were taken and
fractionated into serum, plasma, buffy coat and erythrocytes, and
stored stored in liquid nitrogen. All participants gave written
informed consent and the study was approved by the ethics
committee of the Heidelberg Medical School. Subsequently
participants were contacted three times (every 2–3 years) by
follow-up questionnaires to assess health status; participation rates
of the completed three follow-ups were .90%. Based on all male
EPIC-Heidelberg participants with blood samples available and
free of prevalent cancer (except non-melanoma skin cancer) at
baseline we set up a nested case-control study. Incident prostate
cancer cases diagnosed by end of February 2007 were selected and
two controls were matched per case by age (5-year age groups) and
time of recruitment (6 month intervals) following an incidence
density matching protocol. The final study comprised 248 cases
and 492 controls.
Self-reported cases of prostate cancer were verified by
examination of medical records or death certificates (C61, C63.8
and C63.9; International Classification of Diseases for Oncology,
2nd edition). Tumor grade information (Gleason histologic grade)
was used to categorize cases as high-grade (Gleason score $7),
low-grade (,7) or unknown. Advanced prostate cancer was
defined as prostate cancer with a Gleason sum score $7, TNM
staging score of T3/4, N1-3 or M1 or prostate cancer as
underlying cause of death. During the 2nd and 3rd follow-up
rounds questions addressed history of prostate cancer in 1st degree
relatives and participation in prostate specific antigen (PSA)
screening. Only those cases who participated in screening before
the date of cancer diagnosis were coded as having a positive
screening history. Similarly, only controls participating in screen-
ing before the date of diagnosis were classified as controls
participating in prostate cancer screening. Samples for analysis
during the initial screening phase of genotyping include advanced
prostate cancer cases and one matched control per case.
Genotyping
Genomic DNA was extracted from buffy coat with FlexiGene
Kit (Qiagen, Hilden, Germany) in accordance with the manufac-
turer’s instructions. DNA was stored at 4uC until use. A custom
IlluminaTM GoldenGate assay was designed for analysis of 384
candidate SNPs (tagSNPs and potential functional SNPs) in the
selenoprotein and selenium pathway. Tag SNPs were selected,
using Haploview 3.2, with a cutoff minimum minor allele
frequency (MAF, in CEU population) of 0.05 and pairwise tagging
(r2 = 1-0.8). To include promoter regions and SNPs in LD in
neighboring genes, regions covering the coding region +/22 to15
kbp beyond the 59 and 39 ends were used for the selection.
Selected SNPs were then assessed for suitability for the IlluminaTM
GoldenGate genotyping platform, and the analysis was carried out
on SNPs which were GoldeneGate validated or two-hit validated
with scores .60%. The average call rate was .99%. The list of
SNPs on the chip is presented in Table S1. Genotyping using the
custom chip was carried out by ServiceXs, Leiden, The Nether-
lands.
Subsequently genotyping for selected SNPs (rs9880056 in SELK,
rs7310505 in TXNRD1, rs9605031 and rs9605030 in TXNRD2,
rs28665122 in SEPS1 and rs3211684 in SBP2) was performed as
multiplex on the MassArrayH system (Sequenom, San Diego,
USA) applying the iPLEXH method and MALDI-TOF mass
spectrometry for analyte detection. The analysis was carried out by
Bioglobe (Hamburg, Germany). All duplicated samples (quality
control repeats of 8% of the samples) to verify inter-experimental
reproducibility and accuracy delivered concordant genotype
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results. Similarly a control sample applied on every plate yielded
identical genotypes. All laboratory analyses were carried out with
the laboratory personnel blinded to the case-control status.
GPx Activity, Serum Se and Selenoprotein P
Concentrations
GPx activity was determined with Ransel RS 505 kits (Randox,
Crumlin, UK), as described previously [13,20]. Total serum Se
was determined by dynamic reaction cell-inductively coupled
plasma field mass spectrometry as described previously [13,21].
Coefficients of intra-assay and inter-assay variation have been
reported previously [13]. Serum Selenoprotein P concentration
was measured by an immunoluminometric sandwich assay [22] as
described in detail previously [13]. Six samples had insufficient
amounts of serum to be analyzed.
Statistical Analysis
Baseline characteristics of the study population are given as
mean and standard deviation or percentages by case-control
status. Serum Se and SePP concentrations as well as GPx3 activity
were nearly normally distributed and are presented as mean and
standard deviation.
Among healthy controls, Pearson correlation coefficients were
computed for serum Se, SePP and GPx3 activity. Genotype
frequencies for the selected polymorphisms were computed and
deviations from Hardy-Weinberg equilibrium were determined by
Chi2 test. Conditional logistic regression stratified by the matched
case set was used to calculate odds ratios (OR) and 95%
confidence intervals (CI) for the association of the SNPs with
prostate cancer risk, using the frequent homozygous genotype wild
type as reference category. As reported earlier [13], the final
model included participation in PSA screening, smoking status,
vigorous physical; activity and family history of prostate cancer as
adjustments.
To evaluate potential effect modification of the association
between serum Se concentration and prostate cancer risk by
genotype, we calculated OR (and 95% CI) of prostate cancer for
the continuous variables (serum Se, SePP and GPx) stratified by
genotype with unconditional logistic regression adjusting for the
matching variables (time of recruitment and 5-year age group).
Additionally adjustments were made for family history of prostate
cancer, participation in PSA screening, smoking status and
vigorous physical activity. Due to small numbers in the homozy-
gous mutant genotype we also combined the heterozygote and
homozygote (mutant) categories. We tested for interaction by
comparing the unconditional logistic regression model with and
without crossproduct terms (of genotype and continuous Se
variable) based on the likelihood ratio statistic. This analysis was
repeated in the subgroups according to stage and grade of prostate
cancer. All analyses were performed with SAS 9.1 (SAS Institute,
Cary, USA).
Results
Baseline characteristics of the study population have been
presented previously [13]. Cases and controls were matched for
age and were of comparable BMI. No significant differences were
observed in mean serum concentration of Se or SePP or GPx3
activity between cases and controls [13].
Identification of SNPs Interacting with Se Status Markers
to Determine Prostate Cancer Risk
Genotyping was carried out in two phases. In the initial
hypothesis-generating phase the sub-group of advanced prostate
cancer cases (n = 94) and an equal number of matched controls
were genotyped for 384 SNPs including functional SNPs in
selenoprotein genes and tagging SNPs covering the 25 selenopro-
tein genes and factors important for selenoprotein biosynthesis
(Table S1) selected as described in Materials and Methods.
Genotype alone showed no significant effects of selenoprotein
SNPs on prostate cancer risk. However, taking both genotype and
Se status into account, analysis of all these variants for the 94
advanced prostate cancer cases and controls indicated that a
limited number of SNPs showed a significant interaction with one
or more measures of Se status on prostate cancer risk when the
SNP was considered as either a continuous variable or in a
dominant mode (data not shown). To limit the number of tests on
the whole cohort SNPs were identified which showed statistically
significant interaction with at least one measure of Se status on
prostate cancer risk at the 1% level. Using these criteria,
rs9880056 in SELK, rs9605030 and rs9605031 in TXNRD2,
rs7310505 in TXNRD1, rs3211684 in SBP2 and rs28665122 in
SEPS1 were considered for further study.
Interaction between Genotype and Selenium Status
Affects Prostate Cancer Risk for Selected Individual SNPs
In a second genotyping phase, the full nested case-control study
(248 cases/492 controls) was genotyped for SNPs that showed a
significant interaction with markers of Se status in the first,
pathway analysis, stage (see above: SNPs in TXNRD1, TXNRD2,
SELK, SEPS1 and SBP2). The genotype frequencies are shown in
Table 1. In the controls, genotype frequencies of these five SNPs
were in Hardy-Weinberg equilibrium. There was no statistically
significant main effect of any of these five SNPs on prostate cancer
risk. However, as shown in Table 2, when the influence of Se
status on the effects of genotype for the selected polymorphisms
was taken into account SNPs in TXNRD1 and TXNRD2 genes
were found to influence prostate cancer risk. Firstly, subjects
homozygous for the C allele of rs7310505 in TXNRD1 had an OR
of 0.88 for prostate cancer risk (95% CI = 0.78–1.00, p = 0.045)
per 10 mg/l increase in serum Se concentration, whereas in
subjects carrying the A allele (heterozygous or homozygous) no
association was found (Pinteraction = 0.06). Secondly, subjects
carrying the T allele (heterozygous or homozygous) for
rs9605031 in the TXNRD2 gene had an OR of 0.82 for disease
risk (95% CI = 0.69–0.96, p = 0.016) per 10 mg/l increase in serum
Se concentration, whereas in subjects carrying the homozygous C
no association was found (Pinteraction = 0.02). Interaction terms with
other markers of Se status (serum SePP or GPx activity) did not
reveal significant changes in prostate cancer risk.
Association of Genotype for SNPs in Selenoprotein Genes
with Prostate Tumour Grade and Stage
Analysis of the data for the prostate cancer cases according to
clinical parameters showed that within the study there were 69
advanced cases and 172 cases with localized disease, 90 individuals
with high-grade tumours and 130 with low grade tumours.
Regardless of markers of Se status, when tumour grade and disease
stage were taken into account in the analysis there was a trend
towards reduced risk of a high grade tumour in individuals
carrying at least one T allele for rs28665122 in the gene SEPS1
(OR = 0.57, 95% CI = 0–31–1.06, p = 0.08) (Table 3). Further
analysis of the data incorporating both tumour category and
markers of Se status was carried out. As shown in Table 4, when
analysis was restricted to advanced stage prostate cancer, subjects
homozygous for the C allele of rs7310505 in TXNRD1 had an OR
of 0.72 (95% CI = 0.56–0.93, p = 0.011) per 10 mg/l increase in
Selenoproteins, SNPs and Prostate Cancer
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serum Se concentration, whereas in subjects carrying the A allele
(heterozygous and homozygous) no association was found (pinterac-
tion = 0.02). Similarly, the C allele of rs7310505 was associated with
lower risk of advanced cancer as serum SePP increased (OR 0.43
(95% CI = 0.21–0.88, p = 0.02). In contrast when analysis was
restricted to local stage prostate cancer subjects there was no
significant association of rs7310505 and either serum Se or SePP
concentration with disease risk (Table 4). There was also evidence
of lower risk of advanced prostate cancer in homozygous CC
carriers for rs9605030 in the TXNRD2 gene (OR = 0.53, 95%
CI = 0.29–0.95, p = 0.03) as serum SePP increased. No compara-
ble differences were seen in local stage cancer patients. Restriction
of analysis to subjects with high grade tumours showed that
subjects carrying the T allele for rs28665122 (heterozygous and
homozygous) in the SEPS1 gene (OR = 0.46, 95% CI = 0.24–0.89,
p = 0.02) were at lower risk of a high grade tumour per 10 mg/l
increase in serum Se concentration but no association was
observed in homozygous subjects where pinteraction did not reach
statistical significance (Table 4).
Analysis of the data taking both clinical parameters and
measures of Se status into account showed consistent association
of rs9880056 in the SELK gene with advanced stage or high grade
disease risk. As shown in Table 4, when analysis was restricted to
advanced stage prostate cancer subjects with the C allele
(homozygous and heterozygous) for rs9880056 had an OR of
0.67 (95% CI = 0.50–0.89, p = 0.006) per 10 mg/l increase in
serum Se concentration. Similarly, the C allele of rs9880056 was
associated with lower risk of advanced stage cancer as serum SePP
increased (OR 0.39 (95% CI = 0.16–0.91, p = 0.029). When
analysis was restricted to high grade prostate cancer, subjects
with the C allele (homozygous and heterozygous) for rs9880056
had an OR of 0.76 (95% CI = 0.61–0.94, p = 0.01) per 10 mg/l
increase in serum Se concentration (Table 4), whereas in subjects
homozygous for the T allele no association was found (pinterac-
tion = 0.05). Similarly, the C allele of rs9880056 was associated with
lower risk of high grade tumour as serum SePP increased (OR
0.47 (95% CI = 0.26–0.87, p = 0.016)) with a pinteraction of 0.01. In
addition there was a trend towards carriers of the C allele having a
lower risk of advanced stage disease as serum GPx3 activity
increased (OR = 0.79, 95% CI = 0.61–1.02, p = 0.08). Even when
markers of Se status were included in the analysis no association of
rs9880056 in SELK was found with risk of low grade tumour or
local stage disease.
Discussion
Although previous work has suggested a possible inverse
association between Se levels and risk of prostate cancer [4],
studies of the influence of genetic variants in selenoprotein genes
on prostate cancer risk or survival have been limited [13,17,18].
These earlier studies have provided evidence that variants in a
Table 1. Genotype frequencies of polymorphisms in selected selenoproteins association with prostate cancer risk in the EPIC-
Heidelberg nested case-control study.
Gene RS number Genotype Control N Case N OR (95%CI) p-value
SELK rs9880056 TT 256 122
TC 207 105 1.07 (0.78, 1.47) 0.68
CC 29 21 1.51 (0.83, 2.77) 0.18
TC/CC 236 126 1.12 (0.83, 1.52) 0.47
TXNRD2_1 rs9605030 CC 377 184
CT 104 61 1.18 (0.83, 1.68) 0.36
TT 11 3 0.54 (0.15, 1.97) 0.35
CT/TT 115 64 1.13 (0.80, 1.60) 0.49
TXNRD2_2 rs9605031 CC 272 128
CT 185 98 1.12 (0.82, 1.53) 0.48
TT 35 22 1.32 (0.75, 2.33) 0.34
CT/TT 220 120 1.15 (0.85, 1.55) 0.36
SBP2 rs3211684 TT 436 218
GT 54 28 1.03 (0.65, 1.66) 0.89
GG 2 2 2.01 (0.28, 14.27) 0.49
GT/GG 56 30 1.07 (0.67, 1.69) 0.78
TXNRD1 rs7310505 CC 310 149
CA 161 88 1.14 (0.82, 1.57) 0.43
AA 21 11 1.09 (0.51, 2.32) 0.83
CA/AA 182 99 1.13 (0.83, 1.54) 0.43
SEPS1 rs28665122 CC 365 192
CT 121 53 0.84 (0.59, 1.20) 0.34
TT 6 3 0.98 (0.25, 3.93) 0.98
CT/TT 127 56 0.85 (0.60, 1.20) 0.35
OR, 95% confidence interval (CI) and P values were calculated for each SNP analysed using logistic regression. For each SNP, ORs are presented with reference to the
most frequent homozygous genotype.
doi:10.1371/journal.pone.0048709.t001
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Table 2. Odds ratio and 95% confidence interval for association of serum Se concentration, serum SePP concentration or serum
GPx activity and prostate cancer in strata of genetic polymorphisms.
Gene RS number Genotype Cases/Controls OR (95% CI) p-value
SELK rs9880056
TT 121/254 0.94 (0.81, 1.07) 0.34
TC/CC 123/236 0.89 (0.77, 1.02) 0.09
Pinteraction serum Se 0.46
SELK rs9880056
TT 121/255 0.89 (0.61, 1.28) 0.52
TC/CC 126/236 0.78 (0.54, 1.12) 0.17
Pinteraction serum SePP 0.63
SELK rs9880056
TT 122/256 0.93 (0.79, 1.10) 0.39
TC/CC 126/236 0.93 (0.79, 1.09) 0.36
Pinteraction serum GPx activity 0.97
TXNRD 2_1 rs9605030
CC 182/377 0.95 (0.85, 1.06) 0.39
CT/TT 62/113 0.86 (0.69, 1.08) 0.19
Pinteraction serum Se 0.18
TXNRD2_1 rs9605030
CC 184/376 0.87 (0.65, 1.16) 0.34
CT/TT 63/115 0.85 (0.49, 1.48) 0.57
Pinteraction serum SePP 0.9
TXNRD2_1 rs9605030
CC 184/377 0.92 (0.80, 1.05) 0.21
CT/TT 64/115 0.96 (0.77, 1.19) 0.72
Pinteraction serum GPx activity 0.44
TXNRD2_2 rs9605031
CC 127/272 0.99 (0.88, 1.12) 0.90
CT/TT 117/218 0.82 (0.69, 0.96) 0.02
Pinteraction serum Se 0.02
TXNRD2_2 rs9605031
CC 128/271 0.91 (0.66, 1.27) 0.58
CT/TT 119/220 0.75 (0.49, 1.14) 0.18
Pinteraction serum SePP 0.58
TXNRD2_2 rs9605031
CC 128/272 0.95 (0.81, 1.11) 0.52
CT/TT 120/220 0.93 (0.79, 1.10) 0.40
Pinteraction serum GPx activity 0.93
SBP2 rs3211684
GT/GG 29/56 0.97 (0.65, 1.44) 0.87
TT 215/434 0.92 (0.83, 1.02) 0.12
Pinteraction serum Se 0.65
SBP2 rs3211684
GT/GG 30/56 0.92 (0.32, 2.62) 0.87
TT 217/435 0.84 (0.64, 1.10) 0.20
Pinteraction serum SePP 0.51
SBP2 rs3211684
GT/GG 30/56 0.99 (0.64, 1.55) 0.971
TT 218/436 0.93 (0.83, 1.05) 0.27
Pinteraction serum GPx activity 0.66
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Table 3. Odds ratio and 95% confidence interval for association of polymorphisms in selected selenoproteins with prostate cancer
risk in strata of disease stage.
Advanced cases Localized disease High grade Low grade
Gene RS number Genotype OR(95%CI) p-value OR(95%CI) p-value OR(95%CI) p-value OR(95%CI) p-value
SELK rs9880056 TT 1 1 1 1
TC/CC 0.96 (0.54, 1.69) 0.89 1.26 (0.87, 1.84) 0.22 0.92 (0.55, 1.52) 0.73 1.28 (0.84, 1.95) 0.25
TTXNRD2_1 rs9605030 CC 1 1 1 1
CT/TT 1.4 (0.73, 2.69) 0.31 0.98 (0.64, 1.49) 0.91 1.19 (0.68, 2.08) 0.53 0.88 (0.53, 1.45) 0.61
TXNRD2_2 rs9605031 CC 1 1 1 1
CT/TT 1.09 (0.61, 1.95) 0.77 1.12 (0.78, 1.59) 0.54 0.97 (0.59, 1.58) 0.90 1.09 (0.71, 1.66) 0.69
SBP2 rs3211684 TT 1 1 1 1
GT/GG 1.07 (0.44, 2.64) 0.88 1.09 (0.64, 1.87) 0.7455 1.21 (0.52, 2.84) 0.66 0.92 (0.50, 1.70) 0.80
TXNRD1 rs7310505 CC 1 1 1 1
CA/AA 1.13 (0.63, 2.03) 0.69 1.13 (0.78, 1.63) 0.53 1.18 (0.71, 1.93) 0.52 0.9 (0.59, 1.39) 0.64
SEPS1 rs28665122 CC 1 1 1 1
CT/TT 0.93 (0.50, 1.76) 0.83 0.83 (0.54, 1.27) 0.39 0.57 (0.31, 1.06) 0.08 1.05 (0.66, 1.68) 0.84
OR, 95% confidence interval (CI) and P values were calculated for each SNP analysed using logistic regression and stratified according to disease stage. For each SNP,
ORs are presented with reference to the most frequent homozygous genotype.
doi:10.1371/journal.pone.0048709.t003
Table 2. Cont.
Gene RS number Genotype Cases/Controls OR (95% CI) p-value
TXNRD1 rs7310505
CC 146/310 0.88 (0.78, 1.00) 0.04
CA/AA 98/180 1.03 (0.87, 1.22) 0.72
Pinteraction serum Se 0.06
TXNRD1 rs7310505
CC 149/310 0.84 (0.61, 1.14) 0.26
CA/AA 98/181 0.98 (0.62, 1.57) 0.95
Pinteraction serum SePP 0.47
TXNRD1 rs7310505
CC 149/310 0.89 (0.77, 1.04) 0.15
CA/AA 99/182 1 (0.84, 1.19) 0.97
Pinteraction serum GPx activity 0.16
SEPS1 rs28665122
CC 188/363 0.95 (0.85, 1.06) 0.33
CT/TT 56/127 0.86 (0.68, 1.08) 0.19
Pinteraction serum Se 0.11
SEPS1 rs28665122
CC 191/365 0.87 (0.66, 1.17) 0.36
CT/TT 56/126 0.73 (0.41, 1.29) 0.27
Pinteraction serum SePP 0.3
SEPS1 rs28665122
CC 192/365 0.97 (0.85, 1.11) 0.64
CT/TT 56/127 0.8 (0.61, 1.05) 0.11
Pinteraction serum GPx activity 0.2
OR, 95% confidence interval (CI) and P values were calculated for each SNP analysed using logistic regression. OR adjusted for age group, family history of prostate
cancer, participation in PSA testing, smoking status, and vigorous physical activity. Pinteraction = P value of test for interaction between genotype and serum selenium
concentration per 10 mg/l, serum SePP concentration (mg/l) or serum GPx3 activity per 100 U/l.
doi:10.1371/journal.pone.0048709.t002
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Table 4. Odds ratio and 95% confidence interval for association of markers of Se status and polymorphisms in selenoprotein
genes with advanced and high-grade prostate c cancer in the EPIC-Heidelberg nested case-control study.
Advanced stage Localised disease High grade Low grade










rs9880056 TT 0.94 (0.72, 1.23) 0.64 0.93 (0.78, 1.10) 0.39 1 (0.80, 1.24) 1.00 0.9 (0.75, 1.10) 0.31
rs9880056 TC/CC 0.67 (0.50, 0.89) 0.01 0.97 (0.81, 1.16) 0.76 0.76 (0.61, 0.94) 0.01 1.03 (0.82, 1.29) 0.80
Pinteraction serum Se 0.09 0.91 0.05 0.42
SELK rs9880056
rs9880056 TT 0.78 (0.38, 1.62) 0.51 0.87 (0.55, 1.37) 0.55 1.2 (0.68, 2.11) 0.53 0.65 (0.38, 1.10) 0.11
rs9880056 TC/CC 0.39 (0.16, 0.91) 0.03 0.95 (0.61, 1.46) 0.80 0.47 (0.26, 0.87) 0.02 1.11 (0.67, 1.85) 0.69
Pinteraction serum SePP 0.16 0.71 0.01 0.07
SELK rs9880056
rs9880056 TT 0.78 (0.52, 1.16) 0.22 0.96 (0.80, 1.15) 0.64 1.02 (0.73, 1.43) 0.91 0.84 (0.67, 1.06) 0.14
rs9880056 TC/CC 0.85 (0.59, 1.21) 0.36 0.94 (0.78, 1.13) 0.48 0.79 (0.61, 1.02) 0.08 0.98 (0.75, 1.27) 0.87
Pinteraction serum GPx activity 0.42 0.93 0.13 0.33
TXNRD2_1 rs9605030
rs9605030 CC 0.83 (0.68, 1.03) 0.09 1 (0.87, 1.14) 0.95 0.92 (0.77, 1.10) 0.37 0.97 (0.83, 1.13) 0.69
rs9605030 CT/TT 0.77 (0.41, 1.44) 0.41 0.9 (0.68, 1.18) 0.43 0.7 (0.45, 1.08) 0.10 1.08 (0.74, 1.57) 0.68
Pinteraction serum Se 0.76 0.22 0.05 0.49
TXNRD2_1 rs9605030
rs9605030 CC 0.53 (0.29, 0.95) 0.03 0.98 (0.69, 1.40) 0.93 0.74 (0.47, 1.18) 0.21 0.92 (0.62, 1.37) 0.69
rs9605030 CT/TT 0.56 (0.09, 3.66) 0.55 1.01 (0.52, 1.95) 0.99 0.95 (0.32, 2.76) 0.92 0.8 (0.31, 2.08) 0.65
Pinteraction serum SePP 0.44 0.86 0.74 0.84
TXNRD2_1 rs9605030
rs9605030 CC 0.76 (0.54, 1.07) 0.11 0.94 (0.81, 1.09) 0.43 0.86 (0.67, 1.10) 0.23 0.89 (0.74, 1.08) 0.24
rs9605030 CT/TT 0.85 (0.47, 1.55) 0.60 0.98 (0.76, 1.27) 0.89 0.94 (0.61, 1.44) 0.77 1.08 (0.77, 1.50) 0.66
Pinteraction serum GPx activity 0.29 0.81 0.54 0.27
TXNRD2_2 rs9605031
rs9605031 CC 0.87 (0.68, 1.10) 0.24 1.03 (0.89, 1.19) 0.70 0.94 (0.78, 1.14) 0.53 1 (0.84, 1.20) 0.96
rs9605031 CT/TT 0.72 (0.50, 1.04) 0.08 0.87 (0.71, 1.06) 0.17 0.73 (0.55, 0.97) 0.03 0.98 (0.76, 1.26) 0.85
Pinteraction serum Se 0.68 0.02 0.02 0.63
TXNRD2_2 rs9605031
rs9605031 CC 0.63 (0.32, 1.22) 0.17 0.97 (0.65, 1.44) 0.89 0.7 (0.42, 1.17) 0.17 0.98 (0.63, 1.53) 0.93
rs9605031 CT/TT 0.44 (0.15, 1.27) 0.13 0.96 (0.58, 1.58) 0.87 0.77 (0.38, 1.56) 0.46 0.85 (0.45, 1.60) 0.62
Pinteraction serum SePP 0.71 0.85 0.71 0.83
TXNRD2_2 rs9605031
rs9605031 CC 0.86 (0.58, 1.26) 0.44 0.95 (0.79, 1.14) 0.60 0.88 (0.67, 1.16) 0.38 0.9 (0.72, 1.12) 0.35
rs9605031 CT/TT 0.83 (0.54, 1.26) 0.38 0.96 (0.79, 1.17) 0.72 0.89 (0.66, 1.20) 0.45 0.97 (0.76, 1.23) 0.78
Pinteraction serum GPx activity 0.79 0.82 0.66 0.71
SBP2 rs3211684
SBP2 rs3211684 GT/GG – – – 1.01 (0.63, 1.62) 0.96 – – – 0.97 (0.84, 1.12) 0.66
SBP2 rs3211684 TT 0.84 (0.69, 1.02) 0.08 0.96 (0.85, 1.08) 0.50 0.89 (0.76, 1.04) 0.13 1.33 (0.67, 2.64) 0.42
Pinteraction serum Se 0.54 0.4 0.84 0.48
SBP2 rs3211684
SBP2 rs3211684 GT/GG – – – 1.18 (0.33, 4.21) 0.80 0.72 (0.04, 13.53) 0.83 0.91 (0.62, 1.33) 0.62
SBP2 rs3211684 TT 0.6 (0.34, 1.04) 0.07 0.94 (0.68, 1.29) 0.70 0.75 (0.49, 1.14) 0.18 0.45 (0.06, 3.39) 0.44
Pinteraction serum SePP 0.81 0.48 0.4 0.96
SBP2 rs3211684
SBP2 rs3211684 GT/GG – – – 0.96 (0.58, 1.60) 0.89 0.49 (0.13, 1.85) 0.29 0.92 (0.78, 1.09) 0.34
SBP2 rs3211684 TT 0.85 (0.64, 1.12) 0.24 0.95 (0.83, 1.08) 0.43 0.94 (0.77, 1.14) 0.51 1.02 (0.50, 2.05) 0.97
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combination of the SEPP1 and manganese superoxide dismutase
(SOD2) genes affects disease risk [18], that rs1050450 in GPX1
affects the influence of Se status on risk [13] and that variants in
SEP15 affect prostate cancer survival [17]. Increasingly, it is being
realised that it is important to take an overall biological pathway
approach to identify SNPs that show an association with a disease/
disorder (e.g. [23,24]). The present study used a two-phase
genotyping approach to assess the influence of interaction of Se
status and SNPs in genes across the selenium biological pathway
on prostate cancer risk. The study extended earlier work by
showing consistent significant interactions between serum markers
of Se status and TXNRD1, TXNRD2 and SELK genotype with
respect to risk of high-grade or advanced stage prostate cancer. As
we used tagging-SNPs it is difficult to evaluate the functionality of
these variants. Both TXNRD2 variants and the TXNRD1 variant
studied are intronic and therefore the functional basis for the
observed effects is unclear at present. In contrast, the SNP in SELK
is in the promoter region and thus may influence gene expression
through affecting promoter activity. A more detailed analysis of
the genetic regions, combined with functional assays, could help in
understanding the consequences of these SNPS or variants they
are tagging.
The study involved analysis of samples from the EPIC-
Heidelberg study and benefited from the availability of dietary
and lifestyle data. However, the relatively small number of
participants, particularly in the first phase of analysis, meant that
the study was underpowered. Together with the lack of correction
for multiple testing, this is a limitation that could lead to potential
false positives that could have occurred by chance. However the
strategy chosen here provides the opportunity to potentially
identify new candidate functional SNPs and highlights the
potential role of several selenoproteins in prostate function or
prostate cancer etiology. Additionally, this approach reinforces
previous observations [17] that the effects of some SNPs cannot be
seen when Se status markers are not taken into account.
TR1 and TR2 proteins have major roles in regulation of redox
signalling, whilst SelK has recently been reported to be an
endoplasmic reticulum protein that is thought to play a role in the
unfolded protein response and endoplasmic reticulum homeostasis
[26,27]. Both these biochemical processes are important in cell
responses to metabolic challenges and are thought to be important
in the control of cell proliferation and apoptosis. Therefore the
observed effects of these SNPs are likely to reflect alterations in the
ability of the prostate cells to respond to redox or inflammatory
Table 4. Cont.
Advanced stage Localised disease High grade Low grade









Pinteraction serum GPx activity 0.92 0.42 0.06 0.23
TXNRD1 rs7310505
rs7310505 CC 0.72 (0.56, 0.93) 0.01 0.96 (0.83, 1.11) 0.58 0.83 (0.68, 1.02) 0.07 0.95 (0.80, 1.13) 0.57
rs7310505 CA/AA 0.99 (0.70, 1.40) 0.95 1.02 (0.83, 1.25) 0.83 0.95 (0.73, 1.23) 0.71 1.01 (0.79, 1.30) 0.91
Pinteraction serum Se 0.02 0.54 0.28 0.41
TXNRD1 rs7310505
rs7310505 CC 0.43 (0.21, 0.88) 0.02 1.05 (0.72, 1.52) 0.80 0.74 (0.44, 1.24) 0.25 0.92 (0.61, 1.40) 0.71
rs7310505 CA/AA 1.2 (0.41, 3.53) 0.74 0.83 (0.47, 1.47) 0.51 0.68 (0.32, 1.44) 0.31 0.98 (0.45, 2.11) 0.95
Pinteraction serum SePP 0.02 0.37 0.73 1.00
TXNRD1 rs7310505
rs7310505 CC 0.88 (0.64, 1.22) 0.45 0.9 (0.75, 1.08) 0.25 0.96 (0.73, 1.26) 0.76 0.84 (0.68, 1.04) 0.11
rs7310505 CA/AA 0.78 (0.47, 1.29) 0.34 1.03 (0.84, 1.26) 0.77 0.83 (0.60, 1.15) 0.26 1.11 (0.81, 1.52) 0.51
Pinteraction serum GPx activity 0.93 0.18 0.36 0.02
SEPS1 rs28665122
SEPS1 rs28665122 CC 0.86 (0.70, 1.05) 0.14 1.01 (0.89, 1.15) 0.90 0.9 (0.76, 1.06) 0.22 1 (0.86, 1.18) 0.97
SEPS1 rs28665122 CT/TT 1.09 (0.53, 2.24) 0.81 0.88 (0.68, 1.16) 0.37 0.76 (0.50, 1.17) 0.21 0.89 (0.65, 1.22) 0.48
Pinteraction serum Se 0.48 0.08 0.16 0.22
SEPS1 rs28665122
SEPS1 rs28665122 CC 0.62 (0.34, 1.11) 0.11 1.04 (0.73, 1.48) 0.81 0.8 (0.51, 1.26) 0.34 0.92 (0.61, 1.38) 0.69
SEPS1 rs28665122 CT/TT 1.24 (0.22, 7.17) 0.81 0.85 (0.43, 1.66) 0.63 0.46 (0.18, 1.21) 0.12 0.91 (0.40, 2.08) 0.82
Pinteraction serum SePP 0.94 0.14 0.32 0.78
SEPS1 rs28665122
SEPS1 rs28665122 CC 0.91 (0.67, 1.22) 0.52 0.99 (0.85, 1.15) 0.89 0.95 (0.75, 1.20) 0.68 0.91 (0.75, 1.10) 0.33
SEPS1 rs28665122 CT/TT 0.58 (0.26, 1.30) 0.19 0.88 (0.63, 1.23) 0.45 0.46 (0.24, 0.89) 0.02 0.98 (0.67, 1.44) 0.92
Pinteraction serum GPx activity 0.12 0.2 0.22 0.94
Logistic regression adjusted for matching factors (age and time of blood collection) and family history of prostate cancer, participation in PSA testing, smoking status,
and vigorous physical activity. Data was stratified according to disease stage. Pinteraction = P value of test for interaction between genotype and serum selenium
concentration per 10 mg/l, serum SePP concentration (mg/l) or serum GPx3 activity per 100 U/l.
doi:10.1371/journal.pone.0048709.t004
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challenges. Interestingly, TR1 has been identified as one of four
genes differentially expressed between androgen–dependent and
independent growth of prostate cancer in mice [28]. Over-
activation or dysfunction of thioredoxin reductases have been
proposed to be involved in cancer etiology and prostate tumour
progression [29,30,31]. As a result, thioredoxin reductases have
been identified as anti-cancer targets and small molecules
inhibitors of thioredoxin reductases (such as organoselenium
compounds) are currently used in the treatment of prostate cancer
[30,31]. The observation that SNPs in both TXNRD1 and
TXNRD2 genes are affecting prostate cancer risk supports the
proposed role of the corresponding proteins in prostate function
and/or tumour development. It would be interesting to determine
if genetic variations in these two genes affect individual response to
chemopreventive agents such as thioredoxin reductase inhibitors.
In addition, SelK has been proposed to play a role in the
regulation of Ca2+ flux [32] and changes in Ca2+ flux have been
suggested to be involved in the progression to hormone-insensitive
prostate cancer [33].
The association of SNPs in TXNRD1 and TXNRD2 with disease
risk was only observed in advanced stage or high grade cancers
and not in localized low-grade cases. This may reflect a role for
these selenoproteins in the progression of prostate cancers rather
that initiation, especially in view of the reported relationship
between thioredoxin reductase activity and tumour aggressiveness
[29]; alternatively, there may be different etiologies for the
localized, low grade and the advanced, high grade cancers with
different roles for the selenoproteins in the two disease situations.
We hypothesize that sub-optimal Se status and altered activity of
TR1, TR2 and SelK modify the ability of prostate cells to combat
oxidative and inflammatory challenges and so affect their growth
and tumour progression.
Selenoprotein expression in response to Se supplementation has
been found to vary between individuals and some of these effects
have been attributed to genetic polymorphisms in selenoproteins
[34,35,36]. Synthesis of different selenoproteins responds differ-
entially to sub-optimal Se intake [15,37,38] and since the
protective effects of Se are thought to occur through selenoprotein
biosynthesis one would expect potential genetic effects on prostate
cancer risk to be modulated by Se status and vice versa. Since Se
content of most foods depends on their geographical source Se
intake is difficult to assess [1], but Se status can be assessed by
measurement of blood biomarkers such as serum Se, plasma GPx
or plasma SePP. SePP has been reported to be a better marker of
status over a wider range of intake [12] than GPx3 but a recent
systematic review concluded that more information is needed to
evaluate their strengths and weaknesses as biomarkers of Se status
[11]. Therefore, in this study we measured three markers of Se
status and analysed them independently. There were significant
interactions between Se status and TXNRD1, TXNRD2 and SELK
genotype with respect to high-grade or advanced stage prostate
cancer, so emphasising the importance of the combination of Se
intake and genotype in determining prostate cancer risk. Our
observations that effects of Se-related SNPs on prostate cancer risk
were observed only in combination with Se status provide a likely
explanation of why gene variants in selenoprotein genes have not
been identified as risk factors in a recent genome-wide association
study [25].
The lack of significant association of genotype for single SNPs in
SEPP1 or SEP15 on prostate cancer risk is consistent with earlier
reports that also found no association of specific SNPs in these
genes with prostate cancer risk [17,18]. However, in a nested case
control study [17] variants in SEP15 were observed to be
associated with prostate cancer mortality. In the present study
we were unable to assess effects on mortality.
Large-scale Se supplementation trials in the USA have given
contradictory outcomes with regards to evidence for a relationship
between lower Se intake and increased risk of prostate cancer
[5,6]. This has been attributed to various factors, including higher
baseline Se status in the SELECT study compared with the
Nutritional Prevention of Cancer Trial [6]. The present study was
carried out on European subjects in whom, on the basis of
comparison of earlier populations [2], the mean Se status would be
expected to be lower than in a US population. Indeed, as reported
earlier [13] the mean plasma Se in control subjects within this
study (87.7 mg/l) was lower than the baseline plasma Se in the
recent SELECT trial [6]. In addition, there is evidence for familial
associations of prostate cancer [39] and so it is also possible that
the association between Se status and prostate cancer disease
development may be modified by genetic variation in selenopro-
teins. Such genetic effects have been suggested to contribute to the
differences in the outcomes of the Se supplementation trials [40].
In conclusion, this study shows a significant interaction between
serum markers of Se status and TXNRD1, TXNRD2 and SELK
genotype with respect to high-grade or advanced stage prostate
cancer. This complements a study of the same cohort that focused
on a small number of functional selenoprotein SNPs [13]. The
earlier data showed that genotype for rs1050450 in GPX1 modified
association of serum Se concentration with prostate cancer risk
[13]. It also indicated that there was an association of borderline
statistical between genotype for rs7579 in SEPP1 and prostate
cancer risk [13]. Thus overall, the data from this EPIC-Heidelberg
nested case-control study indicate that together Se status and
GPX1, SEPP1, TXNRD1, TXNRD2, and SELK genotype signifi-
cantly alter risk of high-grade or advanced stage prostate cancer in
a population with suboptimal Se intake. Future studies should not
only address functional effects of these variants in prostate tissue
and but also focus on the larger studies needed to investigate the
complex interplay of polymorphisms in different selenoproteins
and Se status in prostate cancer development. This work also
illustrates that approaches that take multiple SNPs within a
metabolic pathway into account are particularly relevant to the
study of SNP-nutrient interactions in relation to the risk for a
complex disease as they take into consideration the different
components of a biological pathway and nutritional biomarkers;
indeed pathway enrichment methods to analyse data from
genome-wide association studies have been developed [24].
Supporting Information
Table S1 Pathway-wise genotyping for SNPs in selenoprotein
and related genes in control and prostate cancer patients from the
EPIC-Heidelberg cohort. A custom chip was designed for
genotyping across the whole pathway; the SNPs analysed and
the corresponding genes are shown in the two left columns.
Genotyping was carried out on 94 advanced cases and 94 control.
Statistical evaluation of main effects of genetic variants on prostate
cancer risk was carried out using either co-dominant and
dominant models and data stratified for case set.
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